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ABSTRACT
The repair of toxic double-strand breaks (DSB) is
critical for the maintenance of genome integrity. The
major mechanisms that cope with DSB are: homolo-
gous recombination (HR) and classical or alternative
nonhomologous end joining (C-NHEJ versus A-EJ).
Because these pathways compete for the repair of
DSB, the choice of the appropriate repair pathway is
pivotal. Among the mechanisms that inﬂuence this
choice, deoxyribonucleic acid (DNA) end resection
plays a critical role by driving cells to HR, while accu-
rate C-NHEJ is suppressed. Furthermore, end resec-
tion promotes error-prone A-EJ. Increasing evidence
deﬁne Poly(ADP-ribose) polymerase 3 (PARP3, also
known as ARTD3) as an important player in cellu-
lar response to DSB. In this work, we reveal a spe-
ciﬁc feature of PARP3 that together with Ku80 lim-
its DNA end resection and thereby helps in making
the choice between HR and NHEJ pathways. PARP3
interacts with and PARylates Ku70/Ku80. The deple-
tion of PARP3 impairs the recruitment of YFP-Ku80
to laser-induced DNA damage sites and induces an
imbalance between BRCA1 and 53BP1. Both events
result in compromised accurate C-NHEJ and a con-
comitant increase in DNA end resection. Neverthe-
less, HR is signiﬁcantly reduced upon PARP3 silenc-
ing while the enhanced end resection causes muta-
genic deletions during A-EJ. As a result, the absence
of PARP3 confers hypersensitivity to anti-tumoral
drugs generating DSB.
INTRODUCTION
Double-strand breaks (DSB) produced by endogenous
(normalcellmetabolism,replicationlinkederrors)orexoge-
nous (chemotherapeutic drugs) genotoxic agents are con-
sidered as the most cytotoxic forms of deoxyribonucleic
acid (DNA) damage. If unrepaired or inappropriately re-
paired, they will cause cell death or induce genomic insta-
bility and cancer (1). To counteract the effect of DSB, eu-
karyotic cells have evolved two highly efficient repair path-
ways: homologous recombination (HR) and nonhomolo-
gous end joining (NHEJ) (2). HR is initiated by the 5 –3 
resection of the DSB, a process mediated by the Mre11–
Rad50–Nbs1 (MRN) complex in cooperation with CtIP
that catalyses limited resection and the 5 –3  exonucle-
ase Exo1 that catalyses extensive resection (3). A host of
other proteins has been shown to promote DNA end resec-
tion including among others BRCA1, WRN, SMARCAD
(Fun30) and BLM (4–7). The 3  single-stranded overhang
produced is protected by phosphorylated replication pro-
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tein A (RPA). RPA is then replaced by the recombinase
RAD51 that with RAD54 will catalyze the search of ho-
mologous sequences and promote strand invasion of the
template DNA. Because HR requires a homologous tem-
plate, it is thought to operate in S and G2 phases of the
cell cycle. NHEJ consists of two subpathways: the classical
NHEJ pathway (C-NHEJ) and the alternative NHEJ pro-
cess (A-EJ). C-NHEJ is initiated by the association of the
Ku70–Ku80 heterodimer with DNA ends that serves as a
scaffold for the assembly of the other NHEJ factors includ-
ing Aprataxin polynucleotide kinase/phosphatase-like fac-
tor (APLF), DNA–PKcs, Artemis, Cernunnos/XLF and
the XRCC4/DNA ligase IV complex (8,9). C-NHEJ is
thought to process structural compatible ends and is active
throughout the cell cycle (10–13). The alternative pathway
(A-EJ) is initiated by an Mre11-mediated end-resection ac-
tivity in a manner similar to HR and involves additional
proteins such as PARP1, XRCC1, DNA ligase III and hi-
stone H1 (14–20). This process is highly mutagenic repre-
senting a major source of translocations. Recently, in addi-
tion to its important role in HR, BLM has been shown to
prevent CtIP/Mre11-mediated long-range deletion during
A-EJ (21). Similarly, BRCA1 has been proposed to stabilize
Ku80 at broken ends thereby protecting from mutagenic A-
EJ (22).
These different pathways compete for the repair of DSB.
Thus,thechoiceoftheappropriaterepairpathwayispivotal
andisthesubjectofintenseinvestigationsintherepairfield.
Several mechanisms have been shown to be determinant in
directing repair toward HR or NHEJ including signaling
pathways, chromatin modifications, the cell-cycle stage and
the resection of DNA ends, the two latter are believed to
commit cells to repair by HR (2,23). Evidence is building
that the balance between BRCA1 and 53BP1 or between
Ku80 and Mre11 influences DNA end resection and are
therefore determinant of whether repair will occur through
HR or NHEJ (24–29).
Recent studies have defined Poly(ADP-ribose) poly-
merase 3 (PARP3) as a novel player in cellular response
to DSB (30). PARP3 has been described to interact with
partners belonging to the NHEJ pathway including DNA–
PKcs, DNA ligase IV, Ku70 and Ku80 and to accelerate
XRCC4/DNA ligase IV-mediated ligation of chromosomal
DSB in concert with APLF (31,32). Accordingly, PARP3
was found to be efficiently recruited to laser-induced DNA
damage sites (33). It appears that the PAR-dependent in-
teraction of APLF with PARP3 is important for the sub-
sequent ATM-catalysed phosphorylation of APLF and its
retention at damaged DNA (34). As a result, PARP3 de-
pletion in human cells delays the repair of radio-induced
DSB(33).Altogether,thecurrentresearchisconsistentwith
a cooperative role of PARP3 and APLF in the last steps
of NHEJ. However, whether PARP3, that binds chromatin
and DNA in vitro, also regulates early events of DSB repair
still remains enigmatic (32,35).
Inthisstudy,weexaminedhowtheabsenceofPARP3im-
pacts on the repair of DSB by both HR or NHEJ. We used
the radiomimetic drug bleomycin and the topoisomerase II
inhibitor etoposide. We show that PARP3 expression is in-
duced upon etoposide treatment. While we previously re-
ported that its depletion in human cells or its disruption in
micehadnoimpactontheirsurvivalwhenexposedtoioniz-
ing radiation (33),hereweshow thatit significantly reduced
their survival upon etoposide or bleomycin treatment. No-
tably, we found that the absence of PARP3 led to increased
DNA end resection, but the rate of HR measured by using
the HR-reporter substrate is compromised. Because Ku80
has been identified as a modulator of end resection, we fo-
cused our attention on this protein. We identified an asso-
ciation of PARP3 and Ku80 that is enhanced in response to
DSB. PARP3 PARsylates Ku70–Ku80 and facilitates its re-
cruitment to laser-induced DNA damage sites, at one hand
tolimitDNAendresectionduringHR,ontheothertostim-
ulate C-NHEJ. Consequently, PARP3 deficiency impaired
the efficiency of accurate C-NHEJ while causing resection-
mediated mutagenic deletions during A-EJ. In addition, we
identify PARP3 as a novel regulator of the balance between
BRCA1 and 53BP1 that also modulates DSB repair fate.
Together these findings unveil a key contribution of
PARP3 together with Ku80 in the initial events of DSB re-
pairdrivingthechoiceoftheappropriaterepairpathway.In
addition, our results define PARP3 as an interesting ther-
apeutic target to potentialize the cytotoxic effect of DSB-
inducing chemotherapeutic drugs in cancer therapies.
MATERIALS AND METHODS
Reagents, antibodies and plasmids
Antibodies used include: rabbit anti-PARP-3, 4698 for im-
munofluorescence(1:1000),immunoprecipitationandwest-
ern blot (1:10 000) (33); mouse anti-PARP1, EGT69 for
western blot (1:10 000) (36); rabbit anti-phospho RPAS33
and anti-phospho RPAS4S8 for western blot (1:1000, Bethyl
Laboratories) and immunofluorescence (1:2000); mouse
anti-RPA32 for western blot (1:10 000, GeneTex); rab-
bit anti-RPA32 for immunofluorescence (1:2000, AbCam);
rabbit anti-BRCA1 for immunofluorescence (1:500, Milli-
pore); goat anti-Ku70 for western blot (1:500, santa Cruz);
mouse anti-Ku80 for western blot (1:2000, AbCam); mouse
anti-GFP for western blot (1:1000, Roche); rabbit anti-
actin for western blot (1:500, Sigma); mouse anti-RAD54
for immunofluorescence (1:200, Abcam), rabbit anti-53BP1
for immunofluorescence (1:100, Novus Biologicals); rab-
bit anti-Mre11 for western blot (1: 5000, Novus Biolog-
icals); mouse anti-HA.11 for western blot (1:1000, Cov-
ance); peroxidase-conjugated sheep anti-mouse (1:30 000,
GE Healthcare); peroxidase-conjugated goat anti-rabbit
(1:50 000, GE Healthcare) and peroxidase-conjugated rab-
bit anti-goat (1:20 000, Sigma) for ECL detection. Alexa
Fluor-488 goat anti-rabbit IgG or Alexa Fluor-568 goat
anti-rabbit IgG (1:1500, Molecular Probes), Alexa Fluor-
488 goat anti-mouse IgG or Alexa Fluor-568 goat anti-
mouse IgG (1:1500, Molecular Probes) in immunofluores-
cence studies. The PARP inhibitor Ku-0058948 has been
described (37). Etoposide and bleomycin were purchased
fromMylanLaboratoriesInc.NU7441waspurchasedfrom
Selleckchem. YFP–Ku80 has been provided by D. Chen
(University of Texas Southwestern Medical Center, Dallas,
USA). The HA-I-SceI plasmid has been described (15).5618 Nucleic Acids Research, 2014, Vol. 42, No. 9
Cell culture and siRNA-mediated depletion
Control (ctl) and PARP3-depleted (PARP3kd) MRC5 cells
have been described previously (33). MDA-MB231 cells
were grown in Roswell Park Memorial Institute medium
(RPMI) medium supplemented with 10% fetal calf serum
and 1% Gentamicin at 37◦Ci n5 %C O 2.M R C 5w e r e
grown in Dulbecco’s modified Eagle’s medium-1 g/lD -
glucose supplemented with 20% fetal calf serum and 1%
Gentamicin at 37◦Ci n5 %C O 2. The GCV6 cell line
was derived from SV40-transformed GM639 human fi-
broblasts and contains the green fluorescent protein GFP-
based and cluster of differentiation CD4-based substrates
(15,38,39). GCV6 were cultured in Dulbecco’s modified
Eagle’s medium-1 g/l D-glucose containing 10% fetal calf
serum, 1% Gentamicin and supplemented with 3g/ml
blasticidinand350g/mlneomycintomaintaintheexpres-
sion of CD4 and GFP respectively. The 3T3–GFP–Ku80
cells were grown in Dulbecco’s modified Eagle’s medium-1
g/lD-glucosecontaining10%fetalcalfserum,1%Gentam-
icin and supplemented with 2 g/ml puromycin to main-
tain the expression of GFP–Ku80. The U2OS DR–GFP re-
porter cells were used to measure HR as described (40,41).
Gene-specific siRNAs (ON TARGET plus smart pool)
for PARP3 (L-009297), BRCA1 (L-003461), CtIP (L-
0011376), MRE11 (L-009271), Exo1 (L-013120) and neg-
ative control siRNA siCTL (D-001810) were obtained from
Dharmacon. Cells were transfected with 50 nM siRNA us-
ing either JetPrime or Interferin (PolyPlus) according to the
manufacturer’s instructions and processed for the indicated
experiments from 48 h to 72 h later. To confirm the down
regulation of the targeted protein, the transfected cells were
collected 48 h or 72 h after transfection for quantitative re-
verse transcriptase polymerase chain reaction (qRT-PCR)
or western blot analysis respectively.
Colony-forming assay
Exponentially growing cells were treated with etoposide (10
M)orbleomycin(6g/ml)for1h,rinsedtwicewithphos-
phate buffered saline (PBS) and collected by trypsinization.
SiRNA-depleted cells were exposed to the DNA damaging
agents as above 72 h after siRNA transfection, rinsed twice
with PBS and collected by trypsinization. Cells were seeded
at 1500 cells in 100-mm culture dishes in triplicate. Ten days
later, cells were fixed for 30 min in formaldehyde (3.7%),
stained with crystal violet (0.1%) and colonies were scored.
Statistical analysis were determined by ANalysis Of VAri-
ance(ANOVA)testsasindicatedbyPvaluesusingStatView
software.
SCE assay and chromosome analysis
Sister chromatid exchange (SCE) was carried out using a
classical BrdU-labeling protocol. Briefly, cells were treated
with Etoposide (2 M) for 1 h, rinsed with PBS and in-
cubated in culture medium supplemented with BrdU (15
M) for two cell cycles. Metaphase spreads, obtained as
previously described (42), were incubated with 50 g/ml
Hoechst33258for10minandexposedto365nmultraviolet
light(FisherBioblockScientific)for30min.Afterwashings,
metaphaseswerestainedwith4%Giemsa(10min)andcap-
tured with an automated cytogenetic scanner workstation
(MetaSystems). The mean percentages of SCE per chromo-
some ± sem were calculated from 30 metaphases per condi-
tion.
Indirect immunofluorescence microscopy
Immunofluorescence was performed essentially as de-
scribed previously (43). Briefly, cells were grown on glass
coverslips (1×105 cells/ six-well plates) for 48 h, either
mock-treated or treated with 50 M etoposide in triplicate
and released in fresh medium for the indicated time points.
Cells were washed twice with PBS 1X, fixed for 15 min at
25◦C in 4% formaldehyde diluted in PBS 1X–0.1% Triton
X-100–0.1% skimmed milk, and washed again three times
for 10 min at 25◦C with PBS 1X–0.1% Triton X-100–0.1%
skimmed milk. Cells were then incubated overnight at 4◦C
with the appropriate primary antibodies as indicated. Af-
ter three washes for 10 min at 25◦C with PBS–0.1% Tri-
ton X-100–0.1% skimmed milk, cells were incubated with
the appropriate Alexa-labeled secondary antibodies for 2 h
at 25◦C. DNA was counterstained with 4 ,6-diamidino-2-
phenylindol (DAPI; 25 ng/ml in PBS 1X) and slides were
mounted in Mowiol. Images were captured using a Leica
microscope(LeicaMicrosystems)equippedwithanORCA-
ER chilled CCD camera (Hammamatsu) and the capture
software Openlab (Improvision).
Cell extracts, immunoprecipitation and western blot
For whole cell extracts, exponentially growing cells were
lysed by three cycles of freeze/thaw in lysis buffer (20 mM
TrisHCl pH 7.5, 400 mM KCl, 5 mM dithithreitol (DTT),
0.5 mM Pefabloc, 20% glyc´ erol, 0.1% NP40, and protease
inhibitor complex (PIC, Roche)). For PARP3 analysis in
whole cell extracts, cells were lysed in Radioimmunoprecip-
itation assay buffer (RIPA) buffer (50 mM Tris pH 8, 1%
triton, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM
ethylenediaminetetraacetic acid (EDTA), 50 mM NaF, 20
mM sodium pyrophosphate pH 7.2, 1 mM sodium ortho-
tovanadate, 1 mM Pefabloc, PIC) for 10 min at 4◦C. After
centrifugation at 14 000 g at 4◦C for 15 min, cleared sus-
pension was quantified by Bradford protein assay. Nuclear
extracts were prepared according to Groisman et al. (44).
Briefly, cells were suspended in hypotonic buffer (10 mM
TrisHCl pH 7.3, 10 mM KCl, 1.5 mM MgCl2,1 0m M-
mercaptoethanol, 0.2 mM phenylmethanesulfonyl fluoride
(PMSF)). After centrifugation at 2000 g at 4◦C for 5 min,
pellets were resuspended in extraction buffer (15 mM Tris-
HCl pH 7.3, 0.4 M NaCl, 1 mM EDTA, 1 mM MgCl2, 10%
glycerol, 10 mM -mercaptoethanol and 10 mM PMSF).
Samples were incubated on ice for 30 min and centrifuged
at 16 000 g for 30 min at 4◦C. The supernatant was used
as the nuclear extract fraction. Equivalent amounts of pro-
teins were analyzed by 10% SDS–PAGE and immunoblot-
ting. For immunoprecipitation experiments, MDA-MB231
cells (7 × 106) were treated with 50 M etoposide for 1 h
and released in fresh medium. Two hours later, cells were
collected and lysed by incubation in ice for 10 min in RIPA
buffer (50 mM Tris pH 8, 1% triton, 0.5% sodium deoxy-
cholate, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 20 mMNucleic Acids Research, 2014, Vol. 42, No. 9 5619
sodiumpyrophosphatepH7.2,1mMsodiumorthotovana-
date,1mMPefabloc,PIC).Aftercentrifugationat14000×
gat 4◦Cfor15min,theclearedsuspensionwasdilutedindi-
lutionbuffer(150mMNaCl,20mMTris-HClpH7.5,0.1%
NP40, 0.5 mM Pefabloc). After a preclearing with Protein
A Sepharose (GE Healthcare) for 30 min at 4◦C, the cleared
suspensionswereincubatedwitheitherpurifiedanti-PARP-
3 (4698) or rabbit anti-mouse antibody as control overnight
at 4◦C, followed by 3 h incubation at 4◦C with Protein A
Sepharose. After centrifugation at 10 000 rpm at 4◦Cf o r1 5
min, beads were washed once with diluted buffer (250 mM
NaCl, 20 mM Tris-HCl pH 7.5, 0.1% NP40, 0.5 mM Pe-
fabloc), and three times with diluted buffer containing 150
mM NaCl. Final pellets were resuspended in loading buffer
and subjected to 10% SDS/PAGE and immunoblotting.
In vitro (ADP-ribosyl)ation assays
3T3–GFP–Ku80 cells(4×106)werelysedbythreecyclesof
freeze/thawinlysisbuffer(20mMTrisHClpH7.5,400mM
NaCl, 5 mM DTT, 0.5 mM Pefabloc, 20% glyc´ erol, 0.1%
NP40, PIC, 250 nM Ku-0058948). After centrifugation at
10 000 rpm at 4◦C for 20 min, cleared suspension were di-
luted five times in dilution buffer (20 mM TrisHCl pH 7.5,
150 mM NaCl, 0.5 mM Pefabloc, 0.1% NP40, PIC, and 250
nM Ku-0058948) and immunopurified using GFP-Trap R  -
A (Chromotek, Planneg-Martinsried, Germany) for 2–3
ha t4 ◦C. Beads were washed twice with lysis buffer, twice
in dilution buffer containing 400 mM NaCl without Ku-
0058948 and once in Activity buffer (see below). For the
in vitro assays, purified PARP-3 (1 g) was incubated with
equivalent amounts of immunopurified GFP-Ku80 or GFP
for 25 min at 25◦C in 100 l of activity buffer (50 mM Tris-
HCl pH 7.5, 1 mM dithiothreitol, 0.1 mg/ml bovine serum
albumine) containing 50 Ci -32PNAD+ (Perkin Elmer,
800 Ci/mmol) in the presence of 4 g DNase I activated
calf thymus DNA. When indicated Ku-0058948 was added
2 h before lysis and maintained throughout the experiment.
The reaction was stopped by the addition of 500 l of cold
dilution buffer on ice, beads were washed four times with
dilution buffer and resuspended in 20 l Laemmli buffer.
Reaction products were analyzed by gel electrophoresis on
4–20% gradient SDS–PAGE and autoradiography.
Cell-cycle analysis
Control (ctl) and PARP3kd MRC5 cells (1 × 106)w e r e
treated with 5 M etoposide for 3h and released in fresh
medium for the indicated time points. Cells were collected
by trypsinization, washed with PGE (1X PBS, 1% glucose,
1 mM EDTA) and fixed in 70% ethanol in polyethylene gly-
col (PGE) for 24 h at 4◦C. Cells were rehydrated in PGE
for 3 h, treated for 30 min with 100 g/ml RNase I, filtered
and stained with propidium iodure at a final concentration
of 50 g/ml for 30 min at 37◦C. Flow cytometry analysis
was carried out using FACS calibur and Cell Quest Soft-
ware (Becton Dickinson).
In vitro end-joining assay
Plasmid-based assay for in vitro end joining was performed
as described (45). Nuclear extracts were prepared in tripli-
cate from three spleens/sample recovered from eight-week
old Parp3+/+ and Parp3−/− mice (33).
In vivo NHEJ and HR assay
NHEJ was performed essentially as described (15). Briefly,
GCV6 cells (9 × 104) were first transfected with the indi-
cated siRNAs (50 nM) for 48 h and then transfected with
the HA-I-SceI expression vector (pCBASce) for an addi-
tional 48 h. Next, cells were washed with PBS 1X, har-
vested in PBS containing 50 mM EDTA for 5 min to de-
tach the cells and collected in 500 l PBS 1X. After cen-
trifugation at 8000 × g at 4◦C for 15 s, pellets were fixed
with 2% paraformaldehyde (PFA) diluted in PBS for 20
min at room temperature and then PFA was diluted by
addition of 500 l PBS 1X. After centrifugation at 8000
× g at 4◦C for 15 s, supernatants were removed and cells
were stained for 45 min with 2.5 l of the anti-CD4-PE
antibody (MACS) diluted in PBS–BSA 1%. Cells were
washed twice in PBS before FACS analysis. For sequence
junction analysis, we performed polymerase chain reac-
tion (PCR) on genomic DNA using the primers CMV-5,
5 -ATTATGCCCAGTACATGACCTTATG-3  and CD4-
int, 5 -GCTGCCCCAGAATCTTCCTCT-3 . PCR prod-
ucts were cloned into pCRTM4Blunt-TOPO
R   (Invitrogen),
which allowed the isolation of individual clones, and se-
quenced (GATC Biotech).
HR was performed as previously described (40). Briefly,
U2OS cells containing the HR reporter DR–GFP and the
inducible ISceI-GR-mCherry were transfected with 50 nM
oftheindicatedsiRNAfor72h.Nextcellsweretreatedwith
100mg/mloftriamcinoloneacetonide(TA,Sigma)for48h
to induce nuclear translocation of the ISceI-mCherry. An-
alyzing GFP-positive cells out of the mcherry-positive cells
inFACS,analysiswasdoneusingtheFACScaliburandCell
Quest Software (Becton Dickinson).
Laser microirradiation and time-lapse imaging
MDA-MB231weregrownonglasscoverslips(3×103 cells/
six-well plates) for 72 h. Next, cells were first transfected
with control or siPARP3 using JetPrime as detailed above
for48hfollowedbyasecondtransfectionwith0.6gYFP–
Ku80 using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Transfected cells were pro-
cessed for microirradiation studies 17 h later. For local
DNAdamageinduction,cellsweresensitizedbyincubation
in medium containing Hoechst 33342 (6.6 g/ml) for 10
min. Microirradiation and time-lapse imaging was carried
out using an iMIC microscope (Till Photonics) equipped
with a Toptica Laser iBEAM 405 nm and an Olympus 60x
(1.45 NA) objective. During acquisition, cells were main-
tainedat37◦Cina5%CO 2 humidifiedatmosphereusingan
environmentalcontrolsystem(LifeImagingServices).YFP
wasexcitedat491nmwiththemonochromatorPolychrome
V (Till Photonics). For microirradiation, a preselected line
within the nucleus was microirradiated for 10 ms with the
power set to 20% of a 405 nm diode laser. The laser power
measured at the end of the optic fiber was 23.5 mW. Af-
termicroirradiationwide-fieldimageswereacquiredathigh
speed (typically < 70 ms) for 4 s and then every 2 ms for ad-
ditional 15 s on an EMCCD camera (Andor Technology)5620 Nucleic Acids Research, 2014, Vol. 42, No. 9
and analyzed using ImageJ software. For evaluation of the
recruitment kinetics, mean fluorescence intensities of the ir-
radiated region were corrected for loss of fluorescence over
thetimecourseandnormalizedtothepre-irradiationvalue.
Data was fit by nonlinear regression and recruitment curves
were generated using GraphPad Prism 5 (La Jolla, CA).
RESULTS
ThedepletionofPARP3sensitizescellstoanti-tumoraldrugs
generating DSB
We and others have previously defined PARP3 as an impor-
tant player in cellular response to DSB (30,32–34). To sub-
stantiate on these results, we decided to explore the abun-
dance of PARP3 upon the induction of DSB using the
topoisomerase II inhibitor etoposide in two independent
cell lines (Figure 1A and Supplementary Figure S1A). Con-
sistent with the role of PARP3 in DSB repair, etoposide
treatment of MDA-MB231 and MRC5 cells caused a sig-
nificant increase in the nuclear level of PARP3 visible upon
treatment (Figure 1A and Supplementary Figure S1A, left
panels, compare lanes 2 with lanes 1) and maintained up to
5 h after release of the cells in fresh medium (Figure 1Aa n d
Supplementary Figure S1A, left panels, lanes 3–6). In con-
trast,theexpressionofPARP1remainedrather unchanged.
Although less efficiently, the etoposide-induced induction
of PARP3 was also detected in the whole cell extracts of
both cell lines (Figure 1A and Supplementary Figure S1A,
right panels) precluding any protein relocalization.
We previously reported that the depletion of PARP3
in human cells or its disruption in mice did not increase
their long-term sensitivity to X-irradiation (33). Because
X-irradiation produces only 1 DSB for 25 SSB (46), we
postulated that an increase in the ratio of DSB versus sin-
gle strand breaks (SSB) would be cytotoxic to PARP3-
depleted cells. To validate this hypothesis, we compared
the sensitivity of our control (ctl) and PARP3-depleted
(PARP3kd) human cells to anti-tumoral drugs generating
significant amounts of DSB by clonogenic survival assays
(Figure 1B and Supplementary Figure S1Ba-b). We used
the radiomimetic drug bleomycin generating an average of
1 DSB for 6 SSB and the topoisomerase II inhibitor gen-
erating an average of 1 DSB for 10 SSB (47–50). As ex-
pected, the depletion of PARP3 rendered cells hypersensi-
tive to both drugs. A substantial cytotoxicity of both drugs
was also seen in the murine Parp3−/− cells (Supplementary
Figure S1Bc and data not shown). To evaluate the impact
of PARP1, we also compared the sensitivity of the ctl and
thePARP3kd cellstobothdrugsafterchemicalinhibitionof
PARP1 using the potent PARP inhibitor Ku-0058948 (100
nM, a concentration sufficient to inhibit PARP1 in vivo but
not PARP3, data not shown, (33)). Ku-0058948 alone had
no significant effect on the survival of either ctl or PARP3kd
cells (Supplementary Figure S1Bd). While the additional
inhibition of PARP1 further reduced the survival of the
PARP3kd cells exposed to bleomycin (77% loss of survival
after PARP inhibition) likely owing to the reduced PARP1-
mediated repair of the SSBs produced, no significant ad-
ditive effect is observed after exposure to etoposide likely
generating weak amounts of SSB in the experimental con-
ditions used.
Together, these findings emphasize a specific role of
PARP3 in cellular response to DSB while PARP1 responds
preferentially to SSB.
PARP3 promotes DSB repair by NHEJ
PARP3 was initially found to interact with partners be-
longing to the classical NHEJ pathway including DNA–
PKcs, Ku70, Ku80 and APLF (31,32). To question whether
PARP3isneededforefficientNHEJwefirstusedaplasmid-
based in vitro DNA end-joining assay (45) and measured
the capacity of Parp3+/+ and Parp3−/− murine spleen nu-
clear extracts to perform end joining of Sma1- and EcoR1-
linearized plasmids (Figure 2A). Whereas extracts from the
Parp3+/+ cells support efficient end joining leading to the
generation of multimeric forms of the plasmids visualized
on agarose gels, this activity was reduced in Parp3−/− cells
(by 35% for the end joining of blunt ends (Sma1) and by
27% for the end joining of protruding single-stranded ends
(EcoR1)). These results and the previously published func-
tional cooperation between PARP3 and APLF in DSB re-
pair (32) thus suggest that PARP3 operates in NHEJ. We
next aimed to investigate whether PARP3 is implicated
in NHEJ repair at the chromosomal level in mammalian
cells (Figure 2B). We used the previously described GCV6
cell line containing two types of intrachromosomal NHEJ-
reporter substrates: the GFP-based substrate that permits
analysis of the NHEJ on closely adjacent ends separated
by only 34 bp and in which the GFP reporter is located
16 bp from the I-SceI restriction site and the pCOH–CD4
substrate to measure the NHEJ of two distant ends sepa-
rated by 3.2 kb in which the CD4 reporter is located 211 bp
from the I-SceI site (41) (Supplementary Figure S2A). In-
terestingly, the siRNA-mediated PARP3 silencing resulted
in a significant reduction (2-fold reduction) in the end-
joining efficiency of the GFP substrate compared to the
cells transfected with the control siRNA, but did not im-
pair the end-joining efficiency of the CD4 substrate (Fig-
ure 2B, left panel). A similar result was obtained using the
GSC5 cell line containing the same constructs (41) (Sup-
plementary Figure S2B). These results would suggest that
PARP3 is important for the NHEJ of closely adjacent DSB
butmightnotbeinvolvedintheendjoiningofdistantDSB.
Alternatively,thesedatacanbeexplainedbyexcessiveDNA
resection in PARP3-silenced cells resulting in the degrada-
tion of the GFP substrate due to frequent short or inter-
mediate deletions (20–100 bp), while very long deletions (>
200bp)thatwoulddegradetheCD4reporterarerareevents
(38). Resection-mediated intermediate deletions at the re-
sealed junctions have been characterized as the hallmark
of error-prone A-EJ (38,51). To verify our hypothesis fur-
ther and evaluate the impact of PARP3 on the accuracy of
NHEJ,weanalyzedthequalityoftherepairjunctionsbyse-
quencing the end-joining patterns of the CD4 amplification
products(Figure2B,rightpanelandSupplementaryFigure
S2C).Wefoundthat 50% (17/34 events)of theclones trans-
fected with control siRNA exhibited accurate end joining,
whereas this frequency decreased to 26% (9/34 events) in
the PARP3-silenced clones. Conversely, the number of dele-
tions increased from 50% (17/34 events) in the control cells
to 74% (25/34 events) in the PARP3-depleted cells. TheseNucleic Acids Research, 2014, Vol. 42, No. 9 5621
Figure 1. PARP3 responds to and promotes survival upon the induction of double-strand breaks. (A) Enhanced expression of PARP3 upon etoposide
treatment. Upper left panel: MDA-MB231 cells were either mock-treated (lane 1) or exposed to etoposide (Eto, 50 M) (lanes 2–6) for 3 h and then
released in fresh medium for the indicated time points (0 h, indicates no release). Equivalent amounts of nuclear extracts were analyzed by western blotting
using the indicated antibodies. Upper right panel, MDA-MB231 cells were either mock-treated (lane 1) or treated with etoposide (Eto, 50 M, 3 h, lane
2) and equivalent amounts of total protein extracts were analyzed by western blotting as above. Lower panel: representative immunofluorescence pictures
showing the nuclear staining of PARP3 (green) in treated (b and c, Eto, 50 M, 3 h) or nontreated (a, NT) MDA-MB231 cells. In (c), the etoposide
treatment and immunofluorescence were performed 48 h after transfection with siPARP3. Insets: nuclei are stained in blue with DAPI. (B) The depletion
of PARP3 sensitizes cells to DSB-inducing agents. Clonogenic survival of bleomycin-treated (upper panel) or etoposide-treated (lower panel) control (ctl)
and PARP3kd cells in the absence or in the presence of the PARP1 inhibitor Ku-0058948 (100 nM). Experiments were performed >3 times giving similar
results.Meanvaluesoftriplicates±SDareindicated.***P<0.001.ThedepletionofPARP3inthePARP3kd cellswasverifiedbyqRT-PCR(Supplementary
Figure S1Ba).5622 Nucleic Acids Research, 2014, Vol. 42, No. 9
Figure 2. PARP3 promotes DSB repair by NHEJ. (A) Parp3−/− spleen cell extracts display reduced DNA end-joining activity. In vitro end joining of a
Sma1 (blunt)- or EcoR1 (cohesive)-digested plasmid by nuclear cell extracts from Parp3+/+ and Parp3−/− splenocytes. Upper panel: agarose gel stained
with ethidium bromide. Lower panel: the gels were scanned and signal intensities were measured using ImageJ. The value corresponds to the percentage of
dimer and multimer products produced by Parp3−/− extracts relative to the Parp3+/+ extracts set to 100% and represents the mean of three independent
experiments ±SD. *P< 0.05. (B) PARP3-depleted cells are defective in accurate NHEJ. Insets: PARP3 depletion and ISceI expression were verified by
western blotting. Left panel: NHEJ efficiencies in the GCV6 cells treated with the indicated siRNAs. Values represent the means of three independent
experiments (±SD). *P< 0.05. Right panel: analysis of the PCR patterns obtained by amplification of the CD4 fragment after NHEJ-mediated repair in
control (siCTL) and PARP3-silenced (siPARP3) cells. Full-length PCR fragments represent high-fidelity end joining of the junction, whereas shorterP C R
fragments indicate resection-mediated deletions, a hallmark of A-EJ. The silencing of PARP3 resulted in a decrease in high-fidelity end joining and an
increase in the size of the deletions.
results indicate a potential role of PARP3 in promoting ac-
curateC-NHEJ,aspreviouslydescribedforKu80(38).Fur-
thermore, the extent of deletions was significantly larger in
the PARP3-silenced cells with a significant accumulation in
deletions of an intermediate size (20–100 bp) compared to
the control cells thereby suggesting that PARP3 probably
helps to protect DNA ends from increased resection dur-
ing A-EJ similarly to what will be observed during HR de-
scribed later in this study (Figures 3 and 5).
Inanattempttofurtherevaluatetherelativecontribution
of PARP3 in both NHEJ subpathways, we also examined
the sensitivity of the PARP3-depleted cells to etoposide in
conditionswhereoneortheotherofthesubpathwayiscom-
promised (Supplementary Figure S3). To inhibit the classi-
cal NHEJ pathway, we treated the ctl and PARP3kd cells
with the DNA–PK inhibitor NU7441. To inhibit the alter-
native pathway, we examined the effect of the depletion of
DNA ligase III, a key player of the A-EJ (16,52). While the
depletionofPARP3combinedwiththeinhibitionofDNA–Nucleic Acids Research, 2014, Vol. 42, No. 9 5623
Figure 3. PARP3 limits extensive DSB end resection during HR. (A)E n -
hanced etoposide-induced phosphorylation of RPA32 in the absence of
PARP3. Control (ctl) and PARP3-depleted cells (PARP3kd) were treated
with etoposide (Eto, 50 M), harvested at the indicated time points and
processed for western blotting with antibodies against P-RPAS4S8,P -
RPAS33 and RPA. (B) Increased etoposide-induced RPA foci formation in
PARP3-depleted cells. Control (ctl) and PARP3-depleted cells (PARP3kd)
were treated with etoposide (50 M, 1 h), released in fresh medium for
5 h and processed for immunofluorescence using an anti-RPA antibody.
Left panel: the histogram depicts the percentage of cells displaying > 100
RPA foci. An average of 500 cells per condition were scored in > 20 ran-
domly selected fields. Mean values of three independent experiments ±SD
are shown. **P< 0.01. Right panel: representative immunofluorescences
of the quantification of the positive cells with RPA foci (green, asterisks)
are shown. Insets: nuclei are stained in blue with DAPI. (C) Enhanced
etoposide-induced loading of RAD54 in PARP3-depleted cells. Control
(ctl) and PARP3-depleted cells (PARP3kd) were treated with etoposide
(50 M, 1 h) and processed for immunofluorescence at the indicated time
points using an anti-RAD54 antibody. The histogram depicts the percent-
age of cells displaying RAD54 foci. An average of 500 cells per condition
were scored in > 20 randomly selected fields. Mean values of three inde-
pendent experiments ±SD are shown. *P < 0.05; **P< 0.01.
PK further enhanced their sensitivity to etoposide, no ad-
ditive effect was observed upon the combined depletion of
PARP3 and DNA ligase III. Taken together, these findings
suggest a role of PARP3 at the crossroad between classical
and alternative end joining likely to limit mutagenic end re-
section thereby dictating the choice between both subpath-
ways.
PARP3preventsexcessiveDNAendresectionduring HRand
controls the balance between BRCA1 and 53BP1
A drop in the efficiency of DSB repair by NHEJ is often as-
sociatedwithanincreaseintherateofHR(41,53).Further-
more, end resection is critical for the generation of single-
stranded DNA and the sequential loading of RAD51 dur-
ing HR. To determine whether PARP3 also influences end
resection during HR, we aimed to analyze how the deple-
tion of PARP3 affects the etoposide-induced hyperphos-
phorylation of RPA, an event that was previously linked to
efficientDNAendresectionaftergenotoxicstress(54)(F i g -
ure 3A). We found strong increase in the etoposide-induced
hyperphosphorylationofRPAontheresiduesS4S8andS33
in the PARP3kd cells compared to the control cells indicat-
ing enhanced formation of DNA-damage-induced ssDNA
regions. We also quantified the induction of both RPA and
P-RPAS4S8 foci in response to etoposide in both cell lines
and found a sizeable increase in the number of damaged
cells containing RPA and P-RPA foci in the PARP3kd cells
compared to the control cells (Figures 3Ba n d5B, lower
panels). Interestingly, in both the ctl and PARP3kd cells,
we obtained a very similar pattern with almost only a high
number (>100) of small bright foci in the damaged cells.
This observation is likely related to the accumulation of
the cells in S phase at the time point studied (5 h release
upon etoposide treatment) as detailed below (Figure 4C).
Increased DNA end resection has been shown to induce the
formation of a RAD51 nucleofilament on the 3  overhang
to initiate strand invasion on sister chromatids. However,
we were unable to efficiently detect the etoposide-induced
accumulation of RAD51 in our cell lines. Therefore, to con-
firm our observation further, we monitored the formation
of RAD54 to nuclear foci, where it is thought to promote
DNA topological changes aimed to facilitate homologous
DNA pairing (55)( F i g u r e3C). In agreement with the RPA
hyperphosphorylation, we observed enhanced RAD54 foci
formation in PARP3kd cells upon exposure to etoposide
compared to the control cells. Together, these data sug-
gested that the absence of PARP3 induces elevated levels
of DSB end resection during HR as observed above during
A-EJ (Figure 2B).
The initiation of resection is a key determinant of re-
pair pathway choice, which commits cells to HR and pre-
vents repair by classical NHEJ. Genetic studies have estab-
lished that this process is regulated by the balance between
BRCA1 and 53BP1 at DSB chromatin (27,28). While the
accumulation of BRCA1 at DSB promotes HR by displac-
ing 53BP1 from DNA ends, the binding of 53BP1 triggers
NHEJ presumably by inhibiting resection (56,57). Based
on our above results, we wondered whether PARP3 mod-
ulates the competition between both proteins. To address
this question, we analyzed the impact of PARP3 deple-5624 Nucleic Acids Research, 2014, Vol. 42, No. 9
Figure4. PARP3helpstomodulatethebalancebetweenBRCA1and53BP1.(A)IncreasedaccumulationofBRCA1atDSBsitesinPARP3-depletedcells.
Control (ctl) and PARP3-depleted cells (PARP3kd) were treated with etoposide (50 M) for 1 h, released in fresh medium and processed for immunofluo-
rescence at the indicated time points using an anti-BRCA1 antibody. The histogram depicts the percentage of cells displaying >10 BRCA1 foci. An average
of 500 cells per condition were scored in > 20 randomly selected fields. Data are represented as the means of three independent experiments ±SD. *P
< 0.05. Representative immunofluorescences of the quantification of the positive cells with BRCA1 foci (green) are shown. Insets: nuclei are stained in
blue with DAPI. A similar pattern of BRCA1 foci was observed in both cell lines. (B) Decreased loading of 53BP1 in PARP3-depleted cells. Control (ctl)
and PARP3-depleted cells (PARP3kd) were treated with etoposide (50 M) for 1 h, released in fresh medium and processed for immunofluorescence at
the indicated time points using an anti-53BP1 antibody. The histogram depicts the percentage of cells displaying >10 53BP1 foci. An average of 500 cells
per condition were scored in > 20 randomly selected fields. Data are represented as the means of three independent experiments ±SD. *P < 0.05; **P<
0.01. Representative immunofluorescences of the quantification of the positive cells with 53BP1 foci (green) are shown. Insets: nuclei are stained in blue
with DAPI. A similar pattern of 53BP1 foci was observed in both cell lines. (C) PARP3-depleted cells display a similar S-phase delay as control cells after
etoposide treatment but a sustained G2/M arrest. FACS analysis of ctl and PARP3kd cells mock-treated (CTL) or treated with etoposide for 3 h (Eto, 5
M) and released in fresh medium for the indicated time points (0 h (non released), 5 h, 24 h). y axis: cell numbers; x axis: relative DNA content based on
propidium iodide staining.Nucleic Acids Research, 2014, Vol. 42, No. 9 5625
Figure 5. Extensive end resection in the PARP3-depleted cells is mediated by CtIP/Mre11 and Exo1 activities. (A) PARP3-depleted cells display increased
etoposide-induced phosphorylation of Mre11. Control (ctl) and PARP3kd cells were mock-treated (lanes 1–2) or treated with etoposide (50 M, 1 h, lanes
3–4) and harvested for Mre11 and actin immunoblotting (left panel). The DNA damage-induced phosphorylation of Mre11 induces a mobility shift that is
enhancedinPARP3kd cells.Experimentswereperformedthreetimesgivingsimilarresults(rightpanel).Therelativesignalintensitiesofthephosphorylated
versus unphosphorylated Mre11 were measured in the three independent experiments using ImageJ. Mean values ±SD are indicated. (B) Extensive DNA
end resection in the PARP3kd cells is partially rescued by the additional depletion of Mre11 or Exo1. Control (ctl) and PARP3-depleted cells (PARP3kd)
were transfected with the indicated siRNA for 48 h, treated with etoposide (50 M) for 1 h, released in fresh medium for 5 h and processed for BRCA1
(upper panel) and P-RPAS4S8 staining (lower panel). The histograms depict the fold change in the number of cells displaying >10 BRCA1 or >100 P-
RPAS4S8 foci relative to the control. For each experiment, an average of 500 cells per condition were scored in > 20 randomly selected fields. Data are
represented as the means of three independent experiments ±SD. *P < 0.05; **P< 0.01. Representative immunofluorescences of the quantification of the
positive cells with P-RPAS4S8 foci (green) are shown. Insets: nuclei are stained in blue with DAPI. Note the similar pattern of cells with >100 P-RPAS4S8
foci in both cell lines.5626 Nucleic Acids Research, 2014, Vol. 42, No. 9
Figure 6. HR-mediated DSB repair is impaired by the depletion of PARP3. (A) HR efficiency is decreased after PARP3 depletion. The frequency of
HR-mediated repair events was analyzed in U2OS+DR-GFP cells after transfection with the indicated siRNA and nuclear translocation of ISceI induced
by exposure to Triamcinolone Acetonide (TA). The values correspond to the fold decrease of HR efficiency relative to the control (siCTL) and represent
the means of three independent experiments ±SD. **P< 0.01; ***P< 0.001. (B) Etoposide-induced SCE formation is reduced in PARP3-depleted cells.
SCE formation was analyzed in undamaged or etoposide-treated (+Eto) MDA-MB231 cells after transfection with the indicated siRNA. ***P< 0.001.
tion on the assembly of etoposide-induced BRCA1 ver-
sus 53BP1 foci (Figure 4). Consistent with elevated end re-
section and impaired NHEJ, the formation of etoposide-
induced BRCA1 foci was increased in PARP3kd cells com-
pared to control cells (Figure 4A), while the assembly of
53BP1 foci was reduced upon etoposide in the PARP3-
depleted cells compared to the control cells (Figure 4B).
Thus,PARP3helpstomaintainthecorrectbalancebetween
BRCA1-dependent HR and 53BP1-mediated NHEJ.
It has recently been proposed that the antagonism be-
tween BRCA1 and 53BP1 is at least partly influenced by
the cell cycle with the accumulation of 53BP1 at DSB re-
stricted to G1 and the binding of BRCA1 prevailing from
S phase onward (58). Furthermore, DSB resection must be
appropriately restricted to S/G2, as HR requires an intact
sisterchromatidtopromoterepair.Todetermineapotential
contribution of the cell cycle in the extensive end resection,
we compared the cell-cycle distribution after etoposide-
induced DNA damage in the control versus the PARP3kd
cells (Figure 4C). We observed a comparable S-phase arrest
5 h post-treatment in both cell lines indicating that the ex-
tensive end resection observed in the PARP3kd cells cannot
simply be explained by a higher accumulation in S phase
of these cells. In contrast, we observed a more pronounced
G2/M accumulation 24 h post-treatment in the PARP3kd
versus the control cells that can be associated with a higher
accumulation of unrepaired DNA strand breaks (33).
End resection is a two step process during HR initiated
by Mre11 in cooperation with CtIP that carries limited end
resection that is followed by extensive resection catalyzed
by the 5 –3  exonuclease Exo1 alone or in conjunction with
the helicases WRN or BLM (59). Previous reports demon-
strated that Mre11 goes through phosphorylation upon
DNA damage, a post-translational modification required
for its accumulation at repair foci (60,61). To verify that
the increased end resection detected in the PARP3kd cells
is caused by induced activation of Mre11, we followed the
etoposide-induced phosphorylation of Mre11 visualized by
amobilityshiftoftheprotein.Consistentwiththeextensive
DNA end resection, we detected a higher DNA damaged-
induced phosphorylation of Mre11 in the PARP3kd cells
compared to the ctl cells (Figure 5A, compare lane 4 with
lane 3). No phosphorylation was detected in the untreated
cells (lanes 1–2).
To substantiate on these results and confirm that
the enhanced DNA end resection is mediated by either
CtIP/Mre11 or Exo1, we tested whether the siRNA-
mediated knockdown of either Mre11, CtIP or Exo1 would
correct the excessive end resection detected in the PARP3kd
cells (Figure 5B, upper panel and Supplementary Figure
S4). We followed the formation of BRCA1 that accumu-
lates at sites of DNA damage-induced ssDNA (7), 5 h upon
recovery from etoposide treatment, a time point where we
observed a significant difference between ctl and PARP3kd
cells(Figure4A,upperpanel).Asexpected,theknockdown
of either Mre11, CtIP or Exo1 significantly reduced the
increased etoposide-induced accumulation of BRCA1 de-
tected in the PARP3kd cells to the level of untreated con-
trol cells, thereby supporting the conclusion that PARP3-
depleted cells display enhanced strand resection. The factNucleic Acids Research, 2014, Vol. 42, No. 9 5627
Figure 7. PARP3 interacts with and PARsylates Ku70–Ku80, and facilitates its recruitment to laser-induced DNA damage sites. (A) Enhanced association
of PARP3 and Ku80 upon etoposide treatment. MDA-MB231 cells were mock-treated (lanes 1–2) or exposed to etoposide (50 M) for 1 h and released
in fresh medium for 2 h (lane 3). Cell extracts were immunoprecipitated with a control antibody (lane 1) or an anti-PARP3 antibody (lanes 2–3) and
analyzed by western blotting using successively anti-Ku80 and anti-PARP3 antibodies. Input corresponds to 1/16 of the total amount of cell extracts used
for immunoprecipitation. (B) PARP3 PARsylates the Ku70-Ku80 dimer. Immunopurified GFP–Ku80 was incubated with purified PARP3 and assayed for
PARP activity in the absence (lane 1) or in the presence of Ku-0058948 (lanes 2–3). In similar experimental conditions, no PARsylation of GFP alone was
detected. (C) Reduced recruitment of YFP-Ku80 at laser-induced DNA damage sites in PARP3-depleted cells. Left panel: MDA-MB231 cells were treated
with the indicated siRNA for 48 h, transfected with YFP–Ku80 for 17 h and processed for laser microirradiation and live cell imaging as detailed in the
Materials and Methods section. The difference in average fluorescence intensity in the damaged versus undamaged region is plotted against time. Right
panel: a representative example of mock-depleted (siCTL) and PARP3-depleted (siPARP3) cells before and after microirradiation is shown.
that the depletion of Mre11 only weakly (but significantly)
reduces the loading of BRCA1 might be explained by a
remaining resection activity (Supplementary Figure S4B)
or various other pathways promoting BRCA1 recruitment
(62–64). Therefore, to validate these observations further,
wealsomeasuredtheaccumulationofP-RPAS4S8 thatloads
to the single-stranded tails downstream of BRCA1 (Fig-
ure 5B, lower panel). Similarly to BRCA1 foci formation,
the knockdown of Mre11 markedly reduced the accumula-
tion of P-RPAS4S8 induced by etoposide in both the ctl and
PARP3kd cells.
Taken together, these data provide evidence for an in-
volvement of PARP3 in the interplay between BRCA1 and
53BP1 and the regulation of ssDNA resection that is de-
terminant of whether DSB repair ensures by either HR or
NHEJ.
PARP3-depleted cells display reduced homology-directed re-
pair of DSB
We next examined the consequence of the knockdown of
PARP3 on the efficiency of HR-mediated DNA repair. To
this end, we utilized the U2OS cell lines containing the
stably integrated DR-GFP reporter and measured the HR
efficiency induced by ISceI expression after the siRNA-
mediated silencing of PARP3 (Figure 6A). Surprisingly, de-
spite enhanced DNA end resection the reduction of PARP3
induced a significant drop in HR-mediated gene conver-
sion compared to the one observed after depletion of the
HR protein BRCA1 used as a positive control (9-fold de-
crease in BRCA1 silenced cells and 3.5-fold decrease in
PARP3 silenced cells). HR between sister chromatids is the
primary mechanism for SCE induced by genotoxic stress5628 Nucleic Acids Research, 2014, Vol. 42, No. 9
(65–70). Thus to validate this observation further, we tested
whether the reduction of PARP3 would impair etoposide-
induced SCE formation. We performed this experiment
in siRNA-mediated PARP3-silenced MRC5 and MDA-
MB231 cells compared to cells transfected with the control
siRNA (siCTL) (Figure 6B and Supplementary Figure S5).
In line with defective HR, we observed a reduced forma-
tion of SCE after exposure to etoposide in both PARP3-
depleted versus control cells. Together, these data revealed
impaired HR in PARP3-deficient cells despite enhanced
end-resection activity.
PARP3 interacts with Ku80 and facilitates its recruitment to
DNA damaged sites
Previous studies using overeexpressed proteins have identi-
fied an interaction of PARP3 with Ku80 (31). Ku80 was re-
ported to play a determinant role in dictating the choice be-
tween the repair pathways through the regulation of DNA
end resection. After binding to DSB, Ku70/Ku80 must be
actively displaced to allow DNA end resection and thus re-
pair to occur. Its prolonged persistence at break sites was
found to impair HR and accurate NHEJ while similarly to
what we observed in our PARP3kd cells, its depletion was
associatedwithhigherlevelofresectionpartiallydependent
on Exo1 during HR and increased resection-mediated dele-
tional end joining during A-EJ (26,38,53,71). Furthermore,
BRCA1 was found to cooperate with Ku80 at DSB sites
and Mre11 has been implicated in Ku removal (22). Based
on these different observations together with the increased
etoposide-inducedaccumulationofBRCA1fociandtheen-
hanced phosphorylation of Mre11 detected in the absence
of PARP3 (Figure 4Aa n dF i g u r e5A), we speculated that
the relationship between PARP3 and Ku80 might be im-
portant to limit extensive end resection and promote effi-
cient DSB repair. To address this question, we first exam-
ined the association of both partners upon DNA damage
(Figure 7A). Untreated or etoposide-treated whole cell ex-
tracts were immunoprecipitated with an anti-PARP3 anti-
body or an irrelevant antibody and coimmunoprecipitation
of Ku80 was assessed by western blotting. We detected en-
hanced association of PARP3 with Ku80 upon DSB induc-
tion (Figure 7A, compare lane 3 with lane 2). No unspe-
cific immunoprecipitation of Ku80 with the control anti-
body was detected (lane 1).
To gain insights into the functional interaction between
both partners, we evaluated the ability of PARP3 to PAR-
sylate Ku80 (Figure 7B). Immunopurified GFP–Ku80 or
GFPaloneasacontrolwasincubatedtogetherwithpurified
PARP3inthepresenceof-32PNAD+ andDNase-I-treated
calfthymusDNA.WefoundthatPARP3wasabletoweakly
PARsylate GFP–Ku80 and significantly the coprecipitating
Ku70 but not GFP alone (lane 1). The inhibition of PARP3
using the PARP inhibitor Ku-0058948 abolished the PARy-
lation of Ku70 and GFP–Ku80 (lanes 2–3).
To explore the biological relevance of PARP3–Ku80 in-
teraction, we analyzed how PARP3 depletion affects the
accumulation of YFP–Ku80 to laser-induced DNA dam-
age sites (Figure 7C). In agreement with the enhanced DSB
endresection,wefoundthatYFP–Ku80recruitmentwasat-
tenuated in PARP3-silenced cells compared to control cells
indicating that PARP3 likely facilitates the recruitment of
Ku80 to DSB to antagonize DNA end resection but facili-
tate Ku-mediated accurate classical NHEJ.
DISCUSSION
In earlier studies, we and others identified PARP3 as a
newcomer in cellular response to DSB induced by ioniz-
ing radiations (32–34). Mechanistically, PARP3 was pro-
posed to facilitate the phosphorylation and association of
APLF with damaged DNA, which in turn accelerates the
XRCC4/ligaseIV-mediated ligation during NHEJ (32,34).
Whether PARP3 which interacts with the initial sensor of
DSB, namely the Ku70/Ku80 heterodimer (31), also acts in
earlyeventsofDSBrepairdrivingtherepairpathwaychoice
remains unknown. Furthermore, the yield of irradiation-
induced DSB is weak; it is estimated that 1 DSB is created
for 25 SSB. As a result, despite delayed repair of radiation-
induced DSB, long-term sensitivity was not affected by the
absence of PARP3 (33). To clarify these issues, we analyzed
the response of PARP3 to genotoxic compounds inducing
significant levels of DSB and we questioned how PARP3
influences DSB-induced repair by HR versus NHEJ path-
ways.
We document that the nuclear abundance of PARP3
is greatly increased upon etoposide-induced DSB. Con-
sistently, the long-term sensitivity of the PARP3-depleted
cells to genotoxic agents increases with the DSB/SSB ra-
tio. While X-irradiation had no impact (33), the long-term
survival of PARP3-depleted cells was significantly compro-
mised upon exposure to bleomycin and etoposide. Inter-
estingly, we also observed an additive cytotoxic effect of
PARP1 inhibition that seems more important upon expo-
sure to bleomycin than to etoposide. We explain this dif-
ference by a higher accumulation of unrepaired SSB in
bleomycin-treated cells. Together, these data are in strong
support of a specific role of PARP3 in DSB repair while
PARP1 responds to both SSB and DSB (72–75).
Our data also reveal a participation of PARP3 in the
balance between competing DSB repair pathways. The re-
section of DSB to generate single-stranded DNA is a ma-
jor restriction point in the choice between HR and C-
NHEJ and is in competition with DNA end protection
(2,23). In addition, end resection is a hallmark of muta-
genic A-EJ (59). Several processes and proteins modulate
these events. Among them, the association of Ku70–Ku80
to DNA ends favors end protection and promotes accu-
rate C-NHEJ through the recruitment of the core compo-
nents of the repair pathway (10,76). Several studies have
shown that the absence of Ku80 not only impairs accurate
NHEJ but also enhances end resection catalyzed by Exo1
and consequently HR-directed repair (53,71,77). Similarly,
we find that PARP3 depleted-cells display deficient NHEJ,
but enhanced DNA end resection that is marked by in-
creased DNA-damage-induced accumulation of RPA and
RAD54 foci together with accelerated RPA phosphoryla-
tion and increased activation of Mre11. Furthermore, ex-
tensive end resection caused increased deletional end join-
ing during A-EJ as observed in Ku80-deficient cells (38).
Earlier studies have identified an association of PARP3
with Ku80 (31). Here we show that this interaction is in-Nucleic Acids Research, 2014, Vol. 42, No. 9 5629
creased after the induction of DSB and that PARP3 PAR-
sylates the Ku70–Ku80 heterodimer. Together these data
provide evidence for a regulatory role of PARP3 in the re-
pair pathway choice partly by facilitating the recruitment
ofKu80toDNAdamagesites,therebypreventingextensive
DNAendresection.ThediminishedrecruitmentofKu80to
DNA-damaged sites that we observed upon PARP3 silenc-
ing might at one side increase and/or stabilize the binding
of CtIP/Mre11 and Exo1 at DSB sites and consequently
stimulate DSB resection and on the other side compro-
mise efficient and accurate Ku-dependent NHEJ. Support-
ing these results and by analogy to PARP3 in vertebrates,
genetic studies in Dictyostelium identified a third ADP-
ribosyltransferase termed Adprt1a that promotes the re-
cruitement and/or retention of Ku80 to DSB to facilitate
NHEJandpreventHR(78).Accordingly,disruptionofAd-
prt1a decreased the ability of cells to perform end joining
with a concomitant increase in HR. We have yet to deter-
mine how the poly(ADP-ribosyl)ation of Ku70–Ku80 reg-
ulates these events. It has also been reported that PARP3
promotes NHEJ via the recruitment of APLF at damaged
sites, which in turn promotes the recruitment/retention of
XLF and XRCC4–Lig4 for efficient DNA ligation during
C-NHEJ (32). In this molecular complex, Ku80 plays a
critical role in retaining and stabilizing APLF and conse-
quently XRCC4–Lig4 into the Ku–DNA complexes (79).
TheparticipationofPARP3intherecruitmentofKu80and
its poly(ADP-ribosyl)ation reported here define PARP3 as
a key player in the assembly of Ku complexes during C-
NHEJ. As proposed above, this would also help to prevent
extensive resection during HR or A-EJ as it was suggested
for Ku80 (53,80). However, the exact molecular mechanism
involved remains to be clarified. One possibility is that the
PARP3-mediatedretentionofKu80andtherebyAPLFand
XRCC4/lig4 is a way to limit the access of resection en-
zymes to the break. In line with this hypothesis, Ku80 was
shown to inhibit the recruitment of the resection enzyme
Exo1 in human cells and to compete with the MRX/Nr e -
section factors (71,77,81).
Consistent with a regulatory role of PARP3 in the repair
pathway choice, we also found that the absence of PARP3
affects the balance between BRCA1 and 53BP1 at DSB.
Because histone modifications and the chromatin context
are essential determinants of the competition between both
proteins for DSB chromatin association (82,83), it is tempt-
ing to speculate on a possible involvement of PARP3 in
modulating the chromatin state flanking DSB. In line with
this idea, PARP3 has been shown to PARylate histones in
vitro (32,84,85). It will be interesting in future studies to
identify the histones PARylated by PARP3 at DNA lesions
and determine how this influences the pattern of histone
modifications and orchestrates the assembly of the repair
factors at sites of damaged DNA. For example, it has previ-
ously been proposed that histone acetylation regulates the
binding of Ku70/Ku80 at DSB sites (86,87). Similarly, it
is possible that the PARP3-mediated modification of the
chromatin environment at DSB is a way to modulate the
binding and or retention of Ku70/Ku80 to damaged sites.
Furthermore, PARP3 has been described to interact with
the chromatin-associated Polycomb Group (PcG) compo-
nents EZH2, Suz12 and YY1 (31). Beside their role in epi-
genetic gene silencing, PcG proteins have functional rel-
evance in DNA damage repair and genome maintenance
(88). They have been shown to confer protection against
ionizing radiation and accumulate at DNA lesions in a
poly(ADP-ribose)-dependentmanner(89,90).However,the
PARP member involved in this recruitment has not been
clearly identified. PARP3 appears as an ideal candidate.
EZH2 has been proposed to affect DSB repair through
the regulation of BRCA1 (91). Given the increased accu-
mulation of BRCA1 in the PARP3kd cells, it is possible
that PARP3 cooperates with EZH2 to regulate the expres-
sion and/or binding of BRCA1 at sites of damaged DNA.
An other possibility is that the interplay between PARP3
and PcG helps to coordinate DSB repair and transcription
within the chromatin environment as it has been suggested
for PARP1 (74,92).
That the sensitivity of the PARP3-depleted cells to geno-
toxic agents increases with the ratio of DSB/SSB also raises
the possibility that its function in Ku80 recruitment and re-
pair pathway choice is influenced by this ratio. At a bio-
chemical level, this could be explained by a regulated cross
talk between PARP3 in DSB resolution and PARP1 and/or
PARP2 in SSB resolution. Forthcoming studies will help to
clarify this hypothesis.
Surprisingly, despite extensive DNA end resection, HR
as measured using the integrated GFP reporter substrate or
by analyzing DNA-damage-induced SCE is severely com-
promised. Although the mechanism involved is unknown,
these observations imply a blockage of the HR-mediated
repair process at a step downstream of DNA end resection,
during strand invasion as suggested by the higher accumu-
lationofRAD54-containingcells,intheresolutionordisso-
lution of the Holliday junctions or at the final ligation step.
Furthermore, this apparent contradiction questions the in-
terpretationwhetherextensiveendresectionmightsuppress
HR. Alternatively, these results suggest a contribution of
PARP3 to a later step of homology-dependent repair that is
yet to be identified.
In summary, the work presented here provides good ev-
idence that PARP3 limits end resection and thereby helps
makingthedecisionbetweenHRandend-joiningpathways
(HR versus C-NHEJ and/or C-NHEJ versus A-EJ) partly
in cooperation with the Ku70–Ku80 heterodimer, although
thestructureofthechromatinaroundthelesionmayalsobe
important.Furthermore,ourfindingsmayinspirethedevel-
opment of PARP3-specific inhibitors in therapeutic strate-
giesaimedtopotentializethecytotoxicactionofclastogenic
drugs generating high amounts of DSB. Clearly, recent and
ongoing structural and screening studies aimed to identify
PARP3-specificinhibitorswillbevaluableinexploringsuch
strategies (84,93).
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